Mission Therapeutics has dosed the first patient in its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease (PD). MTX325 is a first-in-class, highly potent and selective, orally bioavailable and brain-penetrant inhibitor of the deubiquitinating enzyme (DUB) USP30. It has been designed to… Read More
Scientists funded by Cancer Research UK have discovered a “rising fog” that may cloud the immune system’s ability to detect tumours, potentially helping lung cancer develop years before diagnosis. The team at University College London (UCL), led by Dr James Reading and Professor Sam Janes, were able… Read More
Hosted by Drug Discovery World and supported by Bio-Techne this webinar will explore the advances and challenges taking place within the cell and gene therapy field. You will hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo… Read More
Beam Therapeutics will present initial data from the ongoing Phase I/II clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa) at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT). BEAM-301 is a liver-targeting lipid-nanoparticle (LNP) formulation… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More
News round-up for 12-16 October 2026 by Megan Thomas, Multimedia Editor at DDW. This week’s news roundup covers the upcoming Drug Discovery Innovators & Investors Conference in London, as well as new initiatives to accelerate rare disease drug development, promising preclinical data for Duchenne muscular dystrophy, clinical trial… Read More
New approaches to organising and funding scientific research will be explored at an event in Manchester, UK, on Thursday 5 November, organised by Convergent Research and Advanced Research + Invention Agency (ARIA). The programme will offer two opportunities to discuss Focused Research Organisations (FROs) and their potential role in advancing… Read More
BioNTech has announced the first topline results from the AHEAD-MERIT Phase II/III clinical trial for its investigational mRNA cancer immunotherapy BNT113 (tenumomeran/raplemomeran or tenu-ra). The clinical trial is evaluating BNT113 in combination with pembrolizumab compared to pembrolizumab monotherapy as a first-line treatment for patients with unresectable recurrent… Read More
The US Food and Drug Administration (FDA), a division within the US Department of Health and Human Services (HHS), has announced the Rare Disease Framework Initiative to accelerate the development of drugs and biologics for rare diseases. According to the regulator, the initiative will develop an optimised,… Read More
This digital summit, hosted by DDW and supported by Sino Biological, explores the advances and challenges taking place within the field of immuno-oncology. It will take place on Wednesday, October 21, 2026 at 7am PDT / 10am EDT / 3pm BST / 4pm CEST. Featuring expert presentations and a panel… Read More
Sapreme Therapeutics has shared new preclinical data from its lead Duchenne muscular dystrophy (DMD) programme, SPM-2551, at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society (OTS), taking place in Denver, Colorado, US. SPM-2551 is intended to restore dystrophin to more than 15% of normal levels –… Read More
We are only a few weeks away from DDW’s Drug Discovery Innovators & Investors (DDII) UK Conference that will be held on 4 November 2026 at etc.venues Monument, London. Register by October 16 to secure early bird rates. With its focus on early-stage drug discovery and development, DDII offers insight… Read More
QIAGEN’s new artificial intelligence (AI) capabilities will reportedly help researchers analyse complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis (IPA), and the new QIAGEN Discovery… Read More
Despite a challenging funding landscape, 2026 has seen two groundbreaking advances in mRNA vaccine discovery; the first-ever mRNA seasonal influenza vaccine for adults and the first positive Phase III readout for an mRNA-based cancer therapy. This eBook explores how the mRNA platform has evolved since its use in Covid-19 vaccines,… Read More
Populate, a management platform owned by mixed-use developer Socius, has appointed Dr Angela Kukula as Director of Science and Innovation. Dr Kukula was previously Chief Executive of MedCity and Director of Life Sciences at London & Partners, where she championed London’s life sciences sector on the global… Read More
R&D teams don’t need another chatbot. They need a team that can act on their behalf, guided by the scientists who know the science best. The future of R&D removes the toil of day-to-day work and connects the data scattered across your systems and teams. In this webinar, taking place… Read More
